Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

baxter international inc. - BAX

BAX

Close Chg Chg %
17.13 -0.51 -2.98%

Open Market

16.62

-0.51 (2.98%)

Volume: 4.32M

Last Updated:

Mar 26, 2026, 3:18 PM EDT

Trade Now

Company Overview: baxter international inc. - BAX

BAX Key Data

Open

$16.96

 Day Range

16.62 - 17.50

52 Week Range

16.08 - 34.52

 Market Cap

$8.81B

Shares Outstanding

514.49M

 Public Float

509.64M

Beta

0.58

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.68

Yield

210.28%

 Dividend

$0.01

EX-DIVIDEND DATE

Feb 27, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

11.30M

  

BAX Performance

1 Week
 
 6.01%
 
1 Month
 
 -15.95%
 
3 Months
 
 -11.66%
 
1 Year
 
 -49.27%
 
5 Years
 
 -80.08%
 

BAX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About baxter international inc. - BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

BAX At a Glance

Baxter International, Inc.
One Baxter Parkway
Deerfield, Illinois 60015-4625
Phone 1-224-948-2000 Revenue 11.24B
Industry Medical Specialties Net Income -1,054,000,000.00
Sector Health Technology 2025 Sales Growth 5.716%
Fiscal Year-end 12 / 2026 Employees 37,500
View SEC Filings

BAX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.872
Price to Book Ratio 1.604
Price to Cash Flow Ratio 11.60
Enterprise Value to EBITDA 10.507
Enterprise Value to Sales 1.564
Total Debt to Enterprise Value 0.556

BAX Efficiency

Revenue/Employee 299,840.00
Income Per Employee -28,106.667
Receivables Turnover 5.82
Total Asset Turnover 0.491

BAX Liquidity

Current Ratio 2.314
Quick Ratio 1.562
Cash Ratio 0.663

BAX Profitability

Gross Margin 32.986
Operating Margin 6.163
Pretax Margin -4.491
Net Margin -9.374
Return on Assets -3.927
Return on Equity -13.748
Return on Total Capital -5.657
Return on Invested Capital -5.388

BAX Capital Structure

Total Debt to Total Equity 159.569
Total Debt to Total Capital 61.475
Total Debt to Total Assets 48.766
Long-Term Debt to Equity 158.199
Long-Term Debt to Total Capital 60.947
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Baxter International Inc. - BAX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
15.11B 14.81B 10.64B 11.24B
Sales Growth
+18.22% -1.99% -28.20% +5.72%
Cost of Goods Sold (COGS) incl D&A
9.88B 9.23B 6.78B 7.54B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.40B 1.26B 997.00M 981.00M
Depreciation
650.00M 611.00M 372.00M 383.00M
Amortization of Intangibles
753.00M 652.00M 625.00M 598.00M
COGS Growth
+30.66% -6.63% -26.51% +11.10%
Gross Income
5.23B 5.58B 3.85B 3.71B
Gross Income Growth
+0.19% +6.79% -30.99% -3.76%
Gross Profit Margin
+34.61% +37.70% +36.24% +32.99%
2022 2023 2024 2025 5-year trend
SG&A Expense
3.93B 3.98B 3.17B 3.02B
Research & Development
602.00M 655.00M 510.00M 503.00M
Other SG&A
3.32B 3.33B 2.66B 2.51B
SGA Growth
+25.07% +1.50% -20.53% -4.77%
Other Operating Expense
- - - -
-
Unusual Expense
3.21B 1.09B 711.00M 1.17B
EBIT after Unusual Expense
(1.90B) 507.00M (24.00M) (477.00M)
Non Operating Income/Expense
(28.00M) (92.00M) 137.00M 256.00M
Non-Operating Interest Income
20.00M 70.00M 67.00M 52.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
421.00M 518.00M 402.00M 284.00M
Interest Expense Growth
+176.97% +23.04% -22.39% -29.35%
Gross Interest Expense
432.00M 533.00M 415.00M 298.00M
Interest Capitalized
11.00M 15.00M 13.00M 14.00M
Pretax Income
(2.35B) (103.00M) (289.00M) (505.00M)
Pretax Income Growth
-259.31% +95.62% -180.58% -74.74%
Pretax Margin
-15.57% -0.70% -2.72% -4.49%
Income Tax
68.00M (34.00M) 37.00M 395.00M
Income Tax - Current - Domestic
7.00M 6.00M 40.00M 147.00M
Income Tax - Current - Foreign
286.00M 459.00M 259.00M 171.00M
Income Tax - Deferred - Domestic
(305.00M) (387.00M) (218.00M) 3.00M
Income Tax - Deferred - Foreign
80.00M (112.00M) (44.00M) 74.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(2.42B) (69.00M) (326.00M) (900.00M)
Minority Interest Expense
- 12.00M 7.00M 11.00M
Net Income
(2.43B) (76.00M) (337.00M) (900.00M)
Net Income Growth
-289.49% +96.88% -343.42% -167.06%
Net Margin Growth
-16.10% -0.51% -3.17% -8.00%
Extraordinaries & Discontinued Operations
- (150.00M) (312.00M) (154.00M)
Discontinued Operations
- (150.00M) (312.00M) (154.00M)
Net Income After Extraordinaries
(2.43B) (226.00M) (649.00M) (1.05B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(2.43B) (226.00M) (649.00M) (1.05B)
EPS (Basic)
-4.8274 -0.4466 -1.2726 -2.0546
EPS (Basic) Growth
-288.73% +90.75% -184.95% -61.45%
Basic Shares Outstanding
504.00M 506.00M 510.00M 513.00M
EPS (Diluted)
-4.8274 -0.4466 -1.2726 -2.0546
EPS (Diluted) Growth
-290.99% +90.75% -184.95% -61.45%
Diluted Shares Outstanding
504.00M 506.00M 510.00M 513.00M
EBITDA
2.71B 2.86B 1.68B 1.67B
EBITDA Growth
-8.95% +5.76% -41.18% -0.59%
EBITDA Margin
+17.91% +19.33% +15.83% +14.89%

Snapshot

Average Recommendation HOLD Average Target Price 20.50
Number of Ratings 18 Current Quarters Estimate 0.322
FY Report Date 03 / 2026 Current Year's Estimate 1.916
Last Quarter’s Earnings 0.36 Median PE on CY Estimate N/A
Year Ago Earnings 2.21 Next Fiscal Year Estimate 2.012
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 13 12
Mean Estimate 0.32 0.44 1.92 2.01
High Estimates 0.41 0.47 2.00 2.30
Low Estimate 0.26 0.40 1.84 1.84
Coefficient of Variance 11.63 5.38 2.50 5.55

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 1 1 2
HOLD 14 15 13
UNDERWEIGHT 1 1 1
SELL 0 1 1
MEAN Hold Hold Hold

Insider Actions for Baxter International Inc. - BAX

Date Name Shares Transaction Value
Mar 11, 2026 Joel Todd Grade EVP and CFO 271,674 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.69 per share 4,805,913.06
Mar 11, 2026 Anita A. Zielinski SVP, CAO and Controller 46,281 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.69 per share 818,710.89
Mar 11, 2026 Reaz Rasul EVP,Group Pres,Healthcare 125,557 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.69 per share 2,221,103.33
Mar 11, 2026 David S. Rosenbloom EVP and General Counsel 138,216 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.69 per share 2,445,041.04
Mar 11, 2026 Maria Cecilia Soriano Group Pres., ITT & Pharma. 75,045 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.69 per share 1,327,546.05
Mar 5, 2026 Joel Todd Grade EVP and CFO 103,448 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Andrew P. Hider President and CEO; Director 572,239 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Andrew P. Hider President and CEO; Director 488,506 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 David S. Rosenbloom EVP and General Counsel 144,837 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.69 per share 2,851,840.53
Mar 5, 2026 David S. Rosenbloom EVP and General Counsel 64,655 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Cynthia Carlisle Executive Vice President, CHRO 17,806 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Cynthia Carlisle Executive Vice President, CHRO 29,677 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Cynthia Carlisle Executive Vice President, CHRO 43,103 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Maria Cecilia Soriano Group Pres., ITT & Pharma. 77,894 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.69 per share 1,533,732.86
Mar 5, 2026 Maria Cecilia Soriano Group Pres., ITT & Pharma. 57,471 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 19, 2026 Michael R. McDonnell Director 1,811 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Baxter International Inc. in the News